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Regional, CRC-Distant, and Dead. Quality adjusted life years
were used as the primary outcome measure. The base case analy-
sis represents the overall cost and effectiveness associated with
each screening strategy. Incremental cost-effectiveness ratios
(ICERs) were calculated for each screening strategy. One-way
sensitivity analyses were performed to assess the factors that
have the greatest effect on the cost-effectiveness of screening.
RESULTS: The most cost-effective screening strategy was Fecal
Occult Blood Test (FOBT); followed by FOBT plus aspirin,
colonoscopy, and colonoscopy plus aspirin. The ICER of FOBT
was $13,014.85 compared to natural history or no intervention.
The model was sensitive to the costs of FOBT, colonoscopy, and
aspirin. The screening strategies were sensitive to the cost of
aspirin, FOBT, and colonoscopy. CONCLUSION: Results from
the analysis showed that the most cost-effective screening strat-
egy was the use of FOBT yearly. In terms of only cost, FOBT
was the least expensive screening strategy whereas the most
expensive was colonoscopy plus COX-2 inhibitor. The results
from the study suggest that FOBT and colonoscopy, as well as
these strategies plus aspirin, are the more cost-effective of all the
screening strategies employed. FOBT plus aspirin and col-
onoscopy have similar cost-effectiveness with colonoscopy
having an ICER of only $35.43.
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OBJECTIVES: To compare cost effectiveness of docetaxel
chemotherapy with other adjuvant treatment regimens in early
and locally advanced breast cancer. METHODS: Cost-effective-
ness Markov model from payer perspective (health insurance and
patient), using costs information from published sources and the
patient lifetime horizon. RESULTS: Two comparisons, TAC
(docetaxel/doxorubicin/cyclophosphamide—75/50/500 mg/m2,
6 cycles) vs FAC (ﬂuorouracil/doxorubicin/cyclophophamide—
500/50/500 mg/m2, 6 cycles) and FEC + T (ﬂuorouracil/
epirubicin/cyclophosphamide—500/100/500 mg/m2, 3 cycles +
docetaxel 100 mg/m2, 3 cycles) vs FEC (ﬂuorouracil/epiru-
bicin/cyclophosphamide—500/100/500 mg/m2, 6 cycles), were
performed. One randomized clinical trial was included for each
comparison. Average costs of the treatment of early or locally
advanced breast cancer (including adjuvant chemotherapy, addi-
tional treatment—tamoxifen/radiotherapy, treatment of adverse
events and disease recurrence) and treatment effects were per
patient: TAC 42883 PLN/25,7 LYG vs FAC 8799 PLN/23,6
LYG; FEC + T 32828 PLN/26,1 LYG vs FEC 13505 PLN/24,7
LYG. ICER for TAC vs FAC comparison was 16558 PLN/LYG.
ICER for FEC + T vs FEC was 13 904 PLN/LYG. CONCLU-
SION: Docetaxel regimens are more effective and more expen-
sive in the treatment of patients with early and locally advanced
breast cancer compared with FAC and FEC chemotherapies,
ICER range 13904-16558 PLN/LYG.
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OBJECTIVES: A recent randomized phase III trial of XP vs. con-
tinuous infusional FP as ﬁrst-line therapy in patients with AGC
met its primary endpoint of non-inferior progression-free sur-
vival (PFS). There was a trend toward superior efﬁcacy seen with
the superiority test for PFS (median 5.6 months for XP vs. 5.0
for FP) and the superior response rates of XP. A pharmacoeco-
nomic model was built to compare costs of the two therapies in
an Italian setting. METHODS: Direct medical costs during the
study were estimated from the Italian hospital perspective. Costs
of the two alternative therapies were estimated based on the trial
results on actual dose and the number of administrations, and
Italian unit costs. Adverse event (AE) proﬁles were used to esti-
mate the cost of treating AEs. An expert panel estimated typical
treatment patterns and costs of treating major AEs like anemia
and febrile neutropenia. RESULTS: AE proﬁles were similar:
associated costs to treat major (grade 3/4) AEs were <€170 per
patient and were lower in the XP arm. Patients in the XP arm
received 5.2 cycles of therapy vs. 4.6 cycles of FP. The substitu-
tion of oral capecitabine for infusional 5-FU reduced the number
of hospital clinic visits by 17.6 (22.8 for FP vs. 5.2 for XP).
Chemotherapy drug costs were estimated to be €1200 greater
with XP, but drug administration costs were €2900 lower, yield-
ing a net cost saving of €1700 per patient. CONCLUSION: Oral
capecitabine in combination with cisplatin would produce sig-
niﬁcant direct medical cost savings from an Italian payer per-
spective. AE costs are similar with the two regimens. Given the
trend to superior efﬁcacy, the projected direct cost savings, and
the convenience of oral treatment, XP would be considered a
dominant (less costly and more effective) regimen for AGC from
the Italian payer perspective.
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OBJECTIVES: To estimate the cost-effectiveness of sunitinib
malate versus palliative/best supportive care (BSC) in the treat-
ment of cytokine-refractory metastatic renal cell carcinoma
(mRCC) in patients failing on IL-2, interferon-alpha or combi-
nation of these. METHODS: A Markov model was developed
and adapted to Argentinean circumstances. Effectiveness results
were taken from a clinical trial and a US Medicare database.
Data was adjusted with general population mortality estimates
from Argentinean life tables. Utilities were collected with the
help of EQ-5D questionnaire in the clinical trial. The main
source of resource use and unit costs was an Oncology Institute
in Argentina. Costs were calculated in 2006 Argentinean pesos
(AR$). Both costs and effectiveness were discounted at a 3%
annual rate. Incremental cost-effectiveness was calculated for
progression-free month (PFM), life-year saved (LYS) and quality
adjusted life years (QALY). Both deterministic and probabilistic
sensitivity analyses were undertaken for effectiveness and cost
variables. RESULTS: Compared to BSC, sunitinib resulted in
2.61 extra PFM, 1.32 LYS and 0.98 QALY; however, at an addi-
tional cost of AR$52,243. The cost of gaining one PFM, LYS
and QALY was AR$9596, AR$39,518 and AR$53,445 respec-
tively. The result was most sensitive to effectiveness parameters.
The incremental cost/QALY was always under the US threshold
of $50,000. CONCLUSION: Though treatment with sunitinib
